ArticleWorld journal of urology2026
Development and multicohort validation of an interpretable postoperative model for intravesical recurrence after radical nephroureterectomy in upper tract urothelial carcinoma.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeIntravesical recurrence (IVR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) is frequent, but postoperative recurrence risk is heterogeneous. We developed and multicohort-validated an interpretable postoperative model for IVR risk stratification after RNU.
methodsWe included 813 patients with pathologically confirmed UTUC treated with RNU across four predefined cohorts: retrospective development (n = 400), retrospective external validation (n = 173), internal prospective validation (n = 166), and external prospective validation (n = 74). Missing data were handled using cohort-specific multiple imputation. A Cox model integrating clinicopathological factors and neutrophil-to-lymphocyte ratio (NLR) was developed and locked in the development cohort, then transported unchanged to validation cohorts. Bootstrap confidence intervals, competing-risk analyses, benchmark comparisons, and sensitivity analyses were performed.
resultsThe locked Cox + NLR model retained tumor location, ureteroscopic manipulation, hydronephrosis, pathological stage, surgical margin status, lymphovascular/perineural invasion, history of bladder cancer, and NLR. Harrell's C-indices were 0.709, 0.746, 0.868, and 0.811 across the four cohorts. At the primary 12-month horizon, AUCs were 0.739, 0.771, 0.953, and 0.791, respectively. Low-risk and high-risk groups remained separated under the competing-risk framework. More complex survival machine-learning models did not show a consistent transportability advantage. The 24-month estimates and surveillance simulation were considered exploratory because prospective follow-up was limited.
conclusionThis interpretable postoperative Cox + NLR model showed favorable multicohort performance for IVR risk stratification after RNU. It may support postoperative risk assessment, but prospective implementation studies are needed before surveillance schedules are changed.
Indexed as
Identifiers
42287324What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.